Daniel Nakhaee-Zadeh Gutierrez (@danielnzg85) header
Daniel Nakhaee-Zadeh Gutierrez (@danielnzg85) profile picture

Co-Founder and CTO at @adaptyvbio - @ycombinator alum (S21) - Engineering proteins

Joined February 2011
Photo by Daniel Nakhaee-Zadeh Gutierrez (@danielnzg85)
Daniel Nakhaee-Zadeh Gutierrez retweeted
After almost four months, Mol-1 has officially dethroned OpenDDE to become the #1 open-weight antibody foundation model on cofoldarena.ai. Congrats @jiarlu and @MolenceBio team! All predictions are available to view and download.
Introducing Mol-1: Open Frontier Biomolecular Intelligence 🚀🚀🚀 📊 75.0% on FoldBench-AB, near IsoDDE's reported 75.58%!!! 🧬 60k-token assemblies on one single H20, outperforming Anthropic 8/10. 🎯 VHHs binding hit rate as high as 63% with best SPR KD at 43 pM. GitHub: github.com/molence/Mol-1 Try it: lab.molence.com
5
14
2
128
6,459
Daniel Nakhaee-Zadeh Gutierrez retweeted
TfR1 and KRAS G12D pMHC are both still open!
We're entering the final stretch of the Anthropic x Adaptyv protein design competition Two challenges are still open: • Challenge 4: Blood-brain barrier Design a binder targeting TfR1. Deadline: November 1, 23:59 AoE • Challenge 5: Immunotherapy Design a binder targeting KRAS G12D pMHC. Deadline: November 8, 23:59 AoE ▶️ Make a submission: proteinbase.com/competitions…
4
12
456
Daniel Nakhaee-Zadeh Gutierrez retweeted
🚀 Excited to share BindClaw! 🦀 Starting from a prompt or research paper, BindClaw connects biological mechanisms to protein design: identify targets and binding sites → build mechanism-specific computational assays → generate and assess binders → refine designs using the results. We use agents to evaluate whether designs fit the intended biological objective, including competition with a native partner and preference for a particular molecular state. 🧬 In a human-guided calmodulin campaign, 15 of 18 designs showed binding to calcium-loaded CaM, including subnanomolar binders supported by both BLI and SPR. This work is an incredible team effort together with @DidiKieran , @saint__ai, @ Kyle Gion and @sacdallago and many others! 📄paper/project: research.nvidia.com/labs/dbr… 💻code: will be released in a few weeks!
10
63
6
306
24,238
Daniel Nakhaee-Zadeh Gutierrez retweeted
Time to use the detargeting feature of BindCraft2!
Our last challenge in the Anthropic x Adaptyv Protein Design Competition is about immunotherapy, one of the most important ways of treating cancer. Immunotherapy helps the immune system attack cancer cells, but distinguishing them from healthy cells isn't always easy. In some cancers, the difference can be as subtle as a single amino acid in a small protein fragment. That's the case with KRAS, a protein that works like a growth switch in our cells. In many cancers, a mutation leaves the switch stuck on, and the cell keeps multiplying itself and grows into a tumor. In Challenge 5, you need to design a binder that sticks to the mutated piece of KRAS, but not to the healthy version, so that the immune system can find and attack the cancer cells. The deadline to submit protein designs for this challenge is November 8. Then, we'll pick the best designs and test them in our lab.
3
39
2,179
Daniel Nakhaee-Zadeh Gutierrez retweeted
The last challenge of the Anthropic x Adaptyv competition is live!
Our last challenge in the Anthropic x Adaptyv Protein Design Competition is about immunotherapy, one of the most important ways of treating cancer. Immunotherapy helps the immune system attack cancer cells, but distinguishing them from healthy cells isn't always easy. In some cancers, the difference can be as subtle as a single amino acid in a small protein fragment. That's the case with KRAS, a protein that works like a growth switch in our cells. In many cancers, a mutation leaves the switch stuck on, and the cell keeps multiplying itself and grows into a tumor. In Challenge 5, you need to design a binder that sticks to the mutated piece of KRAS, but not to the healthy version, so that the immune system can find and attack the cancer cells. The deadline to submit protein designs for this challenge is November 8. Then, we'll pick the best designs and test them in our lab.
3
24
1,075
Daniel Nakhaee-Zadeh Gutierrez retweeted
Last but certainly not least: KRAS G12D!
Our last challenge in the Anthropic x Adaptyv Protein Design Competition is about immunotherapy, one of the most important ways of treating cancer. Immunotherapy helps the immune system attack cancer cells, but distinguishing them from healthy cells isn't always easy. In some cancers, the difference can be as subtle as a single amino acid in a small protein fragment. That's the case with KRAS, a protein that works like a growth switch in our cells. In many cancers, a mutation leaves the switch stuck on, and the cell keeps multiplying itself and grows into a tumor. In Challenge 5, you need to design a binder that sticks to the mutated piece of KRAS, but not to the healthy version, so that the immune system can find and attack the cancer cells. The deadline to submit protein designs for this challenge is November 8. Then, we'll pick the best designs and test them in our lab.
1
6
43
2,383
Daniel Nakhaee-Zadeh Gutierrez retweeted
The final challenge in the Anthropic x Adaptyv Protein Design Competition is now live! It’s a really tough specificity challenge, with the off-target peptide differing by just one residue.
Our last challenge in the Anthropic x Adaptyv Protein Design Competition is about immunotherapy, one of the most important ways of treating cancer. Immunotherapy helps the immune system attack cancer cells, but distinguishing them from healthy cells isn't always easy. In some cancers, the difference can be as subtle as a single amino acid in a small protein fragment. That's the case with KRAS, a protein that works like a growth switch in our cells. In many cancers, a mutation leaves the switch stuck on, and the cell keeps multiplying itself and grows into a tumor. In Challenge 5, you need to design a binder that sticks to the mutated piece of KRAS, but not to the healthy version, so that the immune system can find and attack the cancer cells. The deadline to submit protein designs for this challenge is November 8. Then, we'll pick the best designs and test them in our lab.
3
10
1
78
3,511
Daniel Nakhaee-Zadeh Gutierrez retweeted
Our last challenge in the Anthropic x Adaptyv Protein Design Competition is about immunotherapy, one of the most important ways of treating cancer. Immunotherapy helps the immune system attack cancer cells, but distinguishing them from healthy cells isn't always easy. In some cancers, the difference can be as subtle as a single amino acid in a small protein fragment. That's the case with KRAS, a protein that works like a growth switch in our cells. In many cancers, a mutation leaves the switch stuck on, and the cell keeps multiplying itself and grows into a tumor. In Challenge 5, you need to design a binder that sticks to the mutated piece of KRAS, but not to the healthy version, so that the immune system can find and attack the cancer cells. The deadline to submit protein designs for this challenge is November 8. Then, we'll pick the best designs and test them in our lab.
14
19
11
98
18,403
Daniel Nakhaee-Zadeh Gutierrez retweeted
The more I work with powerful AI systems the more optimistic I become about the future of biology. As described in this great post from @citrini it will take time to see the impact of AI across the full complexity of human biology. My view is that drug design is where we are seeing and, in the near term, will continue to see the most visible impact. Drug design is to drug development what coding is to software development. It is the most verifiable step with only weeks or months needed to get results. Solving drug design is necessary but not sufficient and at minimum progress here will reduce the time it takes to bring drugs to patients. My more optimistic vision is that AI will enable us to create drugs beyond our current imagination.
There’s a really pronounced divide between people who are on the AI side of things and people who are on the biology side of things. Even among people working in AI, the divide persists based on where they’re focused. The AI side, adherents of scaling laws and the bitter lesson, believe that AI getting better means AI being more capable of novel discoveries in medicine (that go beyond discovering new drugs in well understood targets or speeding up dry lab work etc). The biology people think the idea of a bitter lesson in biology is kind of ridiculous and that regardless of AI’s capabilities it’s going to be at least 5-10 years until you could hope to reliably simulate human toxicology in silico (right now AI/ML can’t even reliably simulate in vivo studies like binding affinities or functional assays). Even the most AI pilled of them, who will list all the areas that AI can reduce the time spent on various areas, don’t think the concept of AI discovering novel targets or generating new understanding of causal biology is realistic in the near term. Most, in fact, will readily characterize the assumption that even an “ASI” level model could find cures hidden in our current understanding (without expanding that understanding with significantly more biological data) as patently false. This was a big part of why we wanted to experience it ourselves by using AI for a (very) small portion of what it can do in biology. It was both mind blowing and revealed some poignant insights into how different the problem of making AI better at something like coding is to the problems of biology. Even if it unlocked the ability to generate new molecules at a stunning pace, its simulation (in silico) of binding only had 49% accuracy. And if we wanted to improve that, we’d need to feed it back the data from the lab - data that took about 30x as long to get as it took to generate the molecules. And these were tests in a test tube (turn of phrase), imagine how long it would take if we wanted to improve the model with data that required recruiting humans and monitoring their reactions. Human biology is very complex, and adding a drug - especially a novel drug and doubly so for a novel drug acting on a novel mechanism - means mapping interactions that have nth-order-effects that we don’t have the data to predict. Virtual cells have made advancements enabled by AI, but the perturbations equate to a small fraction of the possible. This is before you even get into curing disease, especially uniquely human diseases. Brain function involves cellular identities that are unique to humans, meaning animal studies are of little use. How long does it take to understand what the side effects of chronic administration of a drug in humans are? AI can speed up analyzing the data, or designing the trial or even getting it approved…but it can’t make a 6 month trial complete in 3 months. I think its important to point out that significant advancements can be made in AI that contribute to biology, while also being realistic about how much it speeds up something as complex as curing a specific cancer or diseases of the brain.
6
9
4
121
26,128
Daniel Nakhaee-Zadeh Gutierrez retweeted
We're bringing back design-a-protein.com! Fun story about this website. For our previous protein design competition, we launched it with a cheap and fast protein design pipeline, definitely not state of the art, mostly for educational purposes and to get more people interested in the field. We had pretty low hopes that any of the designs would work, but after synthesizing and testing a few of these vibe-designed proteins in our lab, we found out that one of them actually worked! And it ended up placing #46 in the competition. So, someone with very limited prior biology knowledge saw our launch post, opened the website, clicked a few buttons, generated a protein never seen in nature, and that protein actually performed its intended biological function when synthesized and tested in our lab. One year later, we have a much better option available with the newly released RFD4-Proteina model, which remains as cheap and fast to run, but is much closer to state of the art than our previous pipeline. How many binders can the anon vibe designers create this time? To me, this is one of the clearest examples of how quickly the barriers to drug discovery are falling. And when you combine increasingly accessible and powerful protein design tools with the ability to get your designs synthesized and tested without owning a lab, which is exactly what we're doing at Adaptyv, I think we're going to see tens of thousands of new drug discovery companies emerge. Much like AWS enabled a whole generation of internet startups, I think making biology this accessible will unlock an enormous amount of innovation, hopefully leading to entirely new ways to treat diseases. This is the future we're building towards at Adaptyv.
We built a website to make it super easy to get started with protein design and participate in the Anthropic x Adaptyv protein design competition ▶️ design-a-protein.com This week, we're challenging people to design an Ozempic-like drug. You can get started in just a few clicks, using the newly released RFD4 model to design proteins targeting the GLP-1 receptor. We'll synthesize and test 1000+ of these designs in our automated biology lab, including whether they actually activate the cell receptor, and make all the results publicly available
5
12
1
99
8,059
Daniel Nakhaee-Zadeh Gutierrez retweeted
Please reach out if you're interested in working on ambitious molecule design problems together!
Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find. We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery. I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science. Applications are open for about 14 days: anthropic.com/news/open-call…
9
5
94
6,842
Daniel Nakhaee-Zadeh Gutierrez retweeted
Today, we’re announcing an open call for guest investigators in life sciences. Over 8–12 weeks, guest investigators will work directly with my team and other Anthropic researchers to produce analyses and tools for their work. We’ll run our models and harnesses, at no cost to them. We’ll work together to open-source the resulting data, artifacts, and code, and write preprints about what we find. We want humans to remain at the center of scientific discovery, deciding what questions to pursue, and how to pursue them. Those decisions are not ours to make alone. This open call is part of our ongoing efforts at Anthropic to support researchers and accelerate scientific discovery. I’m looking for principal investigators and their research groups at academic institutions, nonprofits, or government labs, working in causal human biology, structural and computational molecular biology, medicinal chemistry, drug discovery, and clinical science. Applications are open for about 14 days: anthropic.com/news/open-call…
27
59
9
429
82,900
Daniel Nakhaee-Zadeh Gutierrez retweeted
Google Research is also entering the wet lab biology space, using PyLabRobot! Check out the blog post: research.google/blog/groundi… Thanks for the shout out and contributions!
2
4
32
937
Daniel Nakhaee-Zadeh Gutierrez retweeted
still hiring for software engineers btw come help us build the automated biology lab used by the next generation of drug discovery companies!
We're excited to share results from our latest wet lab campaign with @AnthropicAI and @citrini. Claude designed novel proteins to neutralize scorpion toxins and we tested 211 of these protein designs in our automated wet lab. 17 of them showed binding to the toxins in our experiments, with all data now available on @proteinbase. This is a great example of what we're building towards: A world where anyone can run drug discovery campaigns on our automated wet lab.
2
2
20
1,191
Daniel Nakhaee-Zadeh Gutierrez retweeted
TfR1 is our target for the 4th Challenge in the Anthropic x Adaptyv Protein Design Competition. Similar format to EGFR and TNFα: design a pH-sensitive binder that's also cross-reactive.
Challenge 4 of the Anthropic × Adaptyv Protein Design Competition on @proteinbase is open: design a pH-sensitive protein to help shuttle drugs into the brain. TfR1 is a receptor protein that brings iron-loaded transferrin into cells. It is highly expressed in the blood-brain barrier and drug developers can use this receptor to get drugs to pass the blood-brain barrier. The drug is fused to a binder to TfR1, which makes cells absorb the protein complex. If the binder is pH-sensitive it will release from the receptor inside the endosome and then exit the cells on the brain-facing side to deliver the therapeutic into the brain. In this challenge, the goal is to make a pH-sensitive binder to TfR1 that targets precisely the right region on the receptor in order to allow absorption into the cell.
1
7
18
1,129
Daniel Nakhaee-Zadeh Gutierrez retweeted
I can't thank the team @adaptyvbio enough! Claude is a major accelerant and enabler of molecule design, but none of that matters until you see the results in the lab. These scorpion toxins are very tricky to work with and the Adaptyv team was able to quickly express some of them in-house which gave us a lot more confidence in our results 🦂
We're excited to share results from our latest wet lab campaign with @AnthropicAI and @citrini. Claude designed novel proteins to neutralize scorpion toxins and we tested 211 of these protein designs in our automated wet lab. 17 of them showed binding to the toxins in our experiments, with all data now available on @proteinbase. This is a great example of what we're building towards: A world where anyone can run drug discovery campaigns on our automated wet lab.
6
30
2,006
Daniel Nakhaee-Zadeh Gutierrez retweeted
🦂 This was a very fun collaboration with the team @citrini! Thank you to @TwistBioscience and @adaptyvbio for the rapid turnaround on experimental validation and to Susana Vázquez Torres (@CNIOStopCancer), Tim Jenkins (@DTUtweet ), and Dan Bedinger (@carterra_bio) for their thoughtful review. Read more in our blog post: anthropic.com/research/claud…
What is AI really capable of in bio? To separate hype from reality, we spent 3 months working firsthand with @AnthropicAI's internal research model to see if it could create an experimental scorpion antivenom. Introducing Citrini Therapeutics. citriniresearch.com/p/citrin…
10
22
7
232
46,132
Daniel Nakhaee-Zadeh Gutierrez retweeted
We are bringing agents to the wet-lab bench at Google Research to navigate complex biological landscapes. Learn how we are grounding agents in physical lab robotics to run fast closed-loop molecular design cycles, ultimately discovering single-digit nanomolar protein binders for cancer targets →goo.gle/4B5mMMB
4
1
37
3,313
Daniel Nakhaee-Zadeh Gutierrez retweeted
For the first time in an @adaptyvbio competition: functional cell activation assays! Another capability coming online in our biological data gigafactory. Next up... organoids?
Challenge 3 of the Anthropic × Adaptyv Protein Design Competition is open. You have to design a protein that switches on GLP1R, the receptor that semaglutide (Ozempic, Wegovy) and tirzepatide act on in type 2 diabetes and obesity.
4
16
799
Daniel Nakhaee-Zadeh Gutierrez retweeted
GLP-1R is a target we've all heard of. Designing binders against GPCRs is challenging. Agonizing them is next level. Challenge 3 in our competition requires both. We're also extending the duration of each challenge to two weeks, including for Challenge 2: TNFα Good luck!
Challenge 3 of the Anthropic × Adaptyv Protein Design Competition is open. You have to design a protein that switches on GLP1R, the receptor that semaglutide (Ozempic, Wegovy) and tirzepatide act on in type 2 diabetes and obesity.
11
69
3,656